Table 4 Common adverse events of sequential TKI treatment
Adverse events related to first-line treatment with sunitinib | Any grade (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) ** |
|---|---|---|---|---|---|
Any adverse event* | 129 (97) | 20 (15) | 57 (43) | 51 (38) | 1 (1) |
Thrombocytopenia | 39 (30) | 8 (6) | 13 (10) | 17 (13) | 1 (1) |
Neutropenia | 16 (12) | 7 (5) | 3 (2) | 6 (5) | |
HFSR** | 104 (79) | 53 (40) | 37 (28) | 14 (11) | |
Mucositis | 109 (83) | 43 (33) | 42 (32) | 24 (18) | |
Diarrhea | 89 (67) | 51 (39) | 26 (20) | 12 (8) | |
Nausea | 25 (19) | 20 (15) | 5 (4) | 0 (0) | |
Fatigue | 79 (60) | 51 (39) | 22 (17) | 6 (4) | |
High blood pressure | 37 (28) | 23 (17) | 10 (8) | 4 (3) | 0 (0) |
Adverse events related to second-line treatment with sorafenib | |||||
Any adverse event | 123 (93) | 22 (17) | 25 (49) | 37 (28) | 1 (1) |
Hypothyroidism | 38 (29) | 25 (18) | 12 (9) | 1 (1) | – |
HFSR | 105 (80) | 56 (42) | 30 (23) | 19 (14) | |
Rash | 26 (20) | 19 (14) | 5 (4) | 2 (2) | |
Mucositis | 70 (53) | 44 (33) | 20 (15) | 6 (5) | |
Diarrhea | 100 (76) | 51 (39) | 43 (33) | 6 (4) | |
Nausea | 44 (34) | 38 (29) | 5 (4) | 1 (1) | |
Fatigue | 106 (80) | 62 (47) | 35 (27) | 9 (7) | |
High blood pressure | 12 (9) | 4 (3) | 7 (5) | 0 (0) | 1 (1) |